Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Batzelladine O is a guanidine alkaloid natural product isolated from the deep-water marine sponge *Monanchora pulchra*. It exhibits cytotoxic activity against human prostate cancer cell lines, including docetaxel-resistant variants such as PC3-DR and 22Rv1, at low micromolar concentrations. The compound's mechanism of action involves the induction of apoptosis, characterized by caspase-3 and PARP cleavage, and the suppression of the mTOR signaling pathway. Additionally, batzelladine O induces pro-survival autophagy, evidenced by the upregulation of LC3B-II. Research indicates that it is equally active in both docetaxel-sensitive and docetaxel-resistant cells, making it a promising lead candidate for the treatment of taxane-resistant prostate cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on batzelladine O.